These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 517544)

  • 1. Determining the date of manufacture of drug products from lot numbers.
    Feldman MJ; Souney PF; Kaul AF
    Am J Hosp Pharm; 1979 Nov; 36(11):1545-7. PubMed ID: 517544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfite content of drug products.
    Dalton-Bunnow MF
    Am J Hosp Pharm; 1985 Oct; 42(10):2196-201. PubMed ID: 4061462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicians, pharmacists, pharmaceutical manufacturers: partners in patient care, partners in litigation?
    Willig SH
    Spec Law Dig Health Care (Mon); 1987 Feb; 8(12):7-40. PubMed ID: 10280590
    [No Abstract]   [Full Text] [Related]  

  • 4. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability issues of parenteral chemotherapy drugs.
    de Lemos ML; Hamata L
    J Oncol Pharm Pract; 2007 Mar; 13(1):27-31. PubMed ID: 17621564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitfalls of drug manufacturing--an evaluation of 18 months of FDA recalls.
    Frediani HA
    Bull Parenter Drug Assoc; 1972; 26(4):172-81. PubMed ID: 5067998
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 8. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use; required alcohol warning; final rule; compliance date. Food and Drug Administration, HHS.
    Fed Regist; 1999 Mar; 64(51):13066-7. PubMed ID: 10557605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association.
    Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of orphan products.
    FDA Drug Bull; 1983 Apr; 13(1):2-4. PubMed ID: 6852406
    [No Abstract]   [Full Text] [Related]  

  • 13. US manufacturing guideline for IVD products.
    Donawa M
    Med Device Technol; 2000 Oct; 11(8):23-4. PubMed ID: 11185183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The standardization of expiration-date labels.
    Itzchaki S; Lazar E; Deland E
    N Engl J Med; 2006 Jun; 354(23):2515-6. PubMed ID: 16760461
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA drug information that never reaches clinicians.
    Casoy J
    N Engl J Med; 2010 Feb; 362(6):561; author reply 563. PubMed ID: 20175299
    [No Abstract]   [Full Text] [Related]  

  • 16. Recommendations for the labeling of large volume parenterals. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1978 Jan; 35(1):49-51. PubMed ID: 623118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPIs: community pharmacists' perceptions.
    Kaczmarek ER; Stewart JE; Hutchinson RA
    Contemp Pharm Pract; 1982; 5(3):143-9. PubMed ID: 10256917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astringent drug products that produce aluminum acetate; skin protectant drug products for over-the-counter human use; technical amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Mar; 74(43):9759-65. PubMed ID: 19418638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of reserpine injections and tablets submitted by U.S. hospitals.
    Coffman HD; Crabbs WC; Kolinski RE; Page DP
    Am J Hosp Pharm; 1986 Jan; 43(1):103-9. PubMed ID: 3953579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.